Jaguar Animal Health, headquartered in San Francisco and backed by Napo Pharmaceuticals, has closed its series A funding round led by BioVeda China Fund with an investment of $2m.
Jaguar focuses on the development and commercialization of health solutions for the global veterinary marketplace from plants used traditionally in rain forest areas.
The series A funding round was led by BioVeda China Fund (BVCF), a private equity and growth capital investor based in China. It is reported that they were planning to invest an additional $3m by the end of February 2014.
Dr Zhi Yang, MD, PhD and founder and managing director…